# Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

> **NCT01825980** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** BZF961
- **DRUG:** Ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01825980
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01825980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01825980, "Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01825980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*